Affiliations: [a] Neurobiology Research Unit and Center for Integrated Molecular Brain Imaging, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark | [b] PET and Cyclotron Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark | [c] The Memory Clinic, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark | [d] Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark
Correspondence:
[*]
Correspondence to: Karine Madsen, Neurobiology Research Unit, Rigshospitalet N9201, Blegdamsvej 9, 2100 Copenhagen E, Denmark. Tel.: +45 35456708; Fax: +45 35456713; E-mail: [email protected].
Abstract: The 5-HT4 receptor may play a role in memory and learning and 5-HT4 receptor activation has been suggested to modulate acetylcholine release and to reduce amyloid-β (Aβ) accumulation. The aim of this study was for the first time to investigate the in vivo cerebral 5-HT4 receptor binding in early Alzheimer disease (AD) patients in relation to cortical Aβ burden. Eleven newly diagnosed untreated AD patients (mean MMSE 24, range 19–27) and twelve age- and gender-matched healthy controls underwent a two-hour dynamic [11C]SB207145 PET scan to measure the binding potential of the 5-HT4 receptor. All AD patients and eight healthy controls additionally underwent a [11C]PIB PET scan to measure the cortical Aβ burden. When AD patients were defined on clinical criteria, no difference in cerebral 5-HT4 receptor binding between AD patients and healthy controls was found (p = 0.54). However, when individuals were reassigned to groups according to their amyloid status, the PIB-positive individuals had 13% higher 5-HT4 receptor levels than PIB-negative individuals (p = 0.02) and the importance of classification of groups is emphasized. The 5-HT4 receptor binding was a positively correlated to Aβ burden (p = 0.03) and negatively to MMSE score of the AD patients (p = 0.02). Our data suggests that cerebral 5-HT4 receptor upregulation starts at a preclinical stage of and continues while dementia is still at a mild stage, which contrasts other receptor subtypes. We speculate that this may either be a compensatory effect of decreased levels of interstitial 5-HT, an attempt to improve cognitive function, increase acetylcholine release or to counteract Aβ accumulation.
Keywords: 5-HT4 receptor, Alzheimer's disease, amyloid, serotonin, PET
